Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis

Xie, Qinfen; Wang, Lidong; Zheng, Shu

doi:10.1155/2020/1817931

Cited by 13 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data regarding the predictive value of PD-1 and PD-L1 expression on patient outcome are discordant and conflicting. One recent meta-analysis of 11 studies with more than 1000 patients showed that the expression of PD-L1 by tumor cells does not correlate with a worse overall survival of the patients even after stratifying by type of CCA [89] , but another meta-analysis provided opposite results [90] . As for PD-1, recent work has shown that, in iCCA, the increase in CD68 + macrophages and CD8 + T lymphocytes expressing PD-1 correlates with a worse postoperative survival [91] .…”

Section: Adaptive Immunitymentioning

confidence: 99%

Tumor microenvironment and immunology of cholangiocarcinoma

Cadamuro¹,

Fabris²,

Zhang³

et al. 2022

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA), an aggressive tumor originating from both intra- and extra-hepatic biliary cells, represents an unmet need in liver oncology, as treatment remains largely unsatisfactory. A typical feature of CCA is the presence of a complex tumor microenvironment (TME) composed of neoplastic cells, a rich inflammatory infiltrate, and cancer-associated fibroblasts and desmoplastic matrix that makes it extremely chemoresistant to traditional chemotherapeutic drugs. In this review, we describe the cell populations within the TME, in particular those involved in the innate and adaptive immune response and how they interact with tumor cells and with matrix proteins. The TME is crucial for CCA to mount an immune escape response and is the battlefield where molecularly targeted therapies and immune therapy, particularly in combination, may actually prove their therapeutic value.

show abstract

Section: Adaptive Immunitymentioning

confidence: 99%

Tumor microenvironment and immunology of cholangiocarcinoma

Cadamuro¹,

Fabris²,

Zhang³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As such, high levels of tissue Krebs von den Lungen 6 (KL-6 mucin)[ 63 ], cadherin-17 (CDH17)[ 64 ], kallikrein-11[ 65 ], uPAR[ 59 ] and high levels of serum cytokine-induced apoptosis inhibitor 1 (CIAPIN1)[ 66 ], MUC5AC[ 55 ], OPN[ 50 ], S100A6[ 67 ] and uPAR[ 59 , 68 ] were found adverse prognostic factors for CCA patient’s survival. Subjected to meta-analysis, high levels of tissue PD-L1[ 17 ] and tissue protein S100P[ 69 ] were also proposed as potential prognostic markers of CCA. Out of a protein multimarker panel consisting of serum S100A9, MUC5AC, TGF-β1, Ang-2, and CA19-9, serum levels of TGF-β1 and Ang-2 provided predictive potential for both metastasis and TNM stage prognosis in CCA patients[ 62 ].…”

Section: Proteinsmentioning

confidence: 99%

“…Moreover, alteration in targetable pathways [ e.g., fibroblast growth factor receptor 2 gene (FGFR2) involved in MAP kinase signaling, isocitrate dehydrogenase 1 and 2 (IDH1, IDH2)] were also depicted in CCA patients[ 16 ] and currently, several clinical trials are actively recruiting patients. Nevertheless, several microRNAs (miRs) expressions in tissue or deregulated immune responses [expression levels of cytotoxic T-lymphocyte antigen 4 (CTLA-4), forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1)] might have predictive capabilities in CCA patients[ 17 , 18 ]. Many other diagnostic and prognostic tissue-derived biomarkers have already been previously described[ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Novel approaches in search for biomarkers of cholangiocarcinoma

Mocan¹,

Ilieș²,

Melincovici³

et al. 2022

WJG

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic CCA) or more commonly from the extrahepatic bile ducts (extrahepatic CCA). This disease has a poor prognosis and a growing worldwide prevalence. The poor outcomes of CCA are partially explained by the fact that a final diagnosis is challenging, especially the differential diagnosis between hepatocellular carcinoma and intrahepatic CCA, or distal CCA and pancreatic head adenocarcinoma. Most patients present with an advanced disease, unresectable disease, and there is a lack in non-surgical therapeutic modalities. Not least, there is an acute lack of prognostic biomarkers which further complicates disease management. Therefore, there is a dire need to find alternative diagnostic and follow-up pathways that can lead to an accurate result, either singlehandedly or combined with other methods. In the "-omics" era, this goal can be attained by various means, as it has been successfully demonstrated in other primary tumors. Numerous variants can reach a biomarker status ranging from circulating nucleic acids to proteins, metabolites, extracellular vesicles, and ultimately circulating tumor cells. However, given the relatively heterogeneous data, extracting clinical meaning from the inconsequential noise might become a tall task. The current review aims to navigate the nascent waters of the non-invasive approach to CCA and provide an evidence-based input to aid clinical decisions and provide grounds for future research.

show abstract

“…The immune system plays an important role in the pathogenesis of biliary tract tumors [28]. Several studies have shown that PD-L1 expression occurs in half of patients and correlates with a poor prognosis [29]. Immune checkpoint inhibitors have been studied in early clinical trials in patients with biliary tumors.…”

Section: Pd-1/pd-l1 Inhibitionmentioning

confidence: 99%

Cholangiocarcinoma: An Emerging Target for Molecular Therapy

Tsimafeyeu¹,

Temper²

2021

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Cholangiocarcinoma has been traditionally considered a tumor with poor prognosis. Until now, surgical treatment has been the only more or less effective approach. Summary: Over 10 years, chemotherapy with a combination of gemcitabine and cisplatin remains the standard first-line therapy for patients with locally advanced or metastatic cholangiocarcinoma, which leads to a median overall survival of 11.7 months. Several inhibitors of HER (ERBB), HGF/c-MET, Hedgehog, KRAS-BRAF-MEK-ERK, and PI3K/AKT/mTOR signaling pathways did not show their superiority to standard chemotherapy. The rise of hope is associated with the emergence of novel fibroblast growth factor receptors and isocitrate dehydrogenase inhibitors as well as immune checkpoint inhibitors.

show abstract

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis

Cited by 13 publications

References 42 publications

Tumor microenvironment and immunology of cholangiocarcinoma

Tumor microenvironment and immunology of cholangiocarcinoma

Novel approaches in search for biomarkers of cholangiocarcinoma

Cholangiocarcinoma: An Emerging Target for Molecular Therapy

Contact Info

Product

Resources

About